Patents by Inventor Nicolas Stransky

Nicolas Stransky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRKC FUSIONS
    Publication number: 20220213553
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 7, 2022
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas STRANSKY, Joseph L. Kim
  • RAF1 FUSIONS
    Publication number: 20220205045
    Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.
    Type: Application
    Filed: September 30, 2021
    Publication date: June 30, 2022
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas STRANSKY, Joseph L. Kim
  • PRKC fusions
    Patent number: 11261497
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 1, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • PIK3C2G fusions
    Patent number: 10875930
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
  • PRKC FUSIONS
    Publication number: 20200181715
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Application
    Filed: July 16, 2019
    Publication date: June 11, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Joseph L. Kim
  • RAF1 FUSIONS
    Publication number: 20200172981
    Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.
    Type: Application
    Filed: July 16, 2019
    Publication date: June 4, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Joseph L. Kim
  • PIK3CA fusions
    Patent number: 10669590
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Blueprint Medicines Corporation
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20190389969
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fosion proteins, and fragments of those genes and polypeptides.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 26, 2019
    Applicant: Blueprint Medicines Corporation
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • NTRK2 fusions
    Patent number: 10407509
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK, fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 10, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Ethan G. Cerami, Christoph Lengauer
  • RAF1 fusions
    Patent number: 10378063
    Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 13, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • PRKC fusions
    Patent number: 10370724
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 6, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • FGR fusions
    Patent number: 10370725
    Abstract: FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 6, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Ethan G. Cerami
  • TERT fusions
    Patent number: 10370723
    Abstract: The invention provides TERT gene fusions, TERT fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing diseases or disorders associated with TERT fusions, such as conditions mediated by aberrant TERT expression or activity, or overexpression of TERT.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 6, 2019
    Assignee: Blueprint Medicines Corporation
    Inventor: Nicolas Stransky
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS
    Publication number: 20190192522
    Abstract: Described herein are selective inhibitors of FGFR4, pharmaceutical compositions including such compounds, and combinations with other therapeutic agents, such as CDK inhibitors (e.g., CDK4/6 inhibitors), and methods of using such combinations.
    Type: Application
    Filed: September 8, 2017
    Publication date: June 27, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Margit HAGEL, Klaus HOEFLICH, Christoph LENGAUER, Nicolas STRANSKY, Christopher WINTER, Lan XU
  • PIK3CA FUSIONS
    Publication number: 20190185942
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
    Patent number: 10246750
    Abstract: The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: April 2, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • PRKACB FUSIONS
    Publication number: 20170356052
    Abstract: The invention provides PRKACB gene fusions, PRKACB fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated wiih PRKACB fusions, such as conditions mediated by aberrant PRKACB expression or activity or overexpression of PRKACB.
    Type: Application
    Filed: November 17, 2015
    Publication date: December 14, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventor: Nicolas Stransky
  • FGR FUSIONS
    Publication number: 20170211149
    Abstract: FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.
    Type: Application
    Filed: July 15, 2015
    Publication date: July 27, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami
  • PRKC FUSIONS
    Publication number: 20170211148
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Application
    Filed: July 15, 2015
    Publication date: July 27, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Joseph L. Kim
  • TERT FUSIONS
    Publication number: 20170198356
    Abstract: The invention provides TERT gene fusions, TERT fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing diseases or disorders associated with TERT fusions, such as conditions mediated by aberrant TERT expression or activity, or overexpression of TERT.
    Type: Application
    Filed: July 15, 2015
    Publication date: July 13, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventor: Nicolas Stransky